试验观察:基于dna载体的裸抗癌疫苗( Trial watch: Naked and vectored DNA-based anticancer vaccines )

N Bloy A Buqué F Aranda F Castoldi A Eggermont I Cremer C Sautès-Fridman J Fucikova J Galon R Spisek adjuvants dendritic cell electroporation GX-188E mucosal immunity VGX-3100 AFP, α-fetoprotein APC, antigen-presenting cell CDR, complementarity-determining region CEA, carcinoembryonic antigen CIN, cervical intraepithelial neoplasia CTLA4, cytotoxic T lymphocyte protein 4 DAMP, damage-associated molecular pattern DC, dendritic cell FDA, Food and Drug Administration GM-CSF, granulocyte macrophage colony-stimulating factor HCC, hepatocellular carcinoma HNSCC, head and neck squamous cell carcinoma HPV, human papillomavirus IL, interleukin OS, overall survival OVA, ovalbumin PAP, prostate acid phosphatase SCGB2A2, secretoglobin, family 2A, member 2 SOX2, SRY (sex determining region Y)-box 2 T, brachyury homolog TAA, tumor-associated antigen TLR, Toll-like receptor TRA, tumor rejection antigen Treg, regulatory T cell WT1, Wilms tumor 1

一种类型的抗癌疫苗依赖于对编码一种或多种肿瘤相关抗原（TAAs）的DNA构建体的施用。这些制剂的最终目的是在免疫刺激环境中驱动TAAs的合成，导致（再）诱导肿瘤靶向免疫应答，这些制剂可以是裸的或由非致病性病毒、细菌或酵母细胞载体的，其最终目的是在免疫刺激环境中驱动TAAs的合成，从而导致（再）诱导肿瘤靶向免疫应答。尽管有令人鼓舞的临床前结果，但以DNA为基础的疫苗在癌症患者中作为独立的免疫治疗干预措施的临床疗效似乎是有限的。因此，目前正致力于开发组合方案，使基于DNA的抗癌疫苗能够引发临床相关的免疫应答。在这里，我们讨论最近的进展在临床前和临床发展这一治疗范式。

SciDown文献求助系统（解决99%问题） Public Download 万方 Taylor & Francis NCBI ResearchGate Europe PMC 掌桥科研 onAcademic pubfacts.com mendeley.com dx.doi.org mysciencework.com Taylor & Francis ResearchGate Europe PMC